切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2025, Vol. 14 ›› Issue (06) : 925 -930. doi: 10.3877/cma.j.issn.2095-3232.2025.06.017

临床研究

肝癌肝动脉持续灌注化疗患者卧床时限改变的前瞻性研究
朱恒美, 董志涛, 房树恒(), 贺丹丹, 张晓丽, 周静, 翟健, 耿利, 杨甲梅   
  1. 200438 上海,海军军医大学第三附属医院特需诊疗科
  • 收稿日期:2025-06-22 出版日期:2025-12-10
  • 通信作者: 房树恒
  • 基金资助:
    上海市“医苑新星”青年医学人才资助(202265); 海军军医大学深蓝护理课题(2022KYG39); 海军军医大学第三附属医院“腾飞工程”优护人才项目(202429); 中华医学会护理学科研究课题(CMAPH-NR(2025024)); 海军军医大学第三附属医院(25HL001)

Prospective study on change of bed rest duration in liver cancer patients undergoing continuous hepatic arterial infusion chemotherapy

Hengmei Zhu, Zhitao Dong, Shuheng Fang(), Dandan He, Xiaoli Zhang, Jing Zhou, Jian Zhai, Li Geng, Jiamei Yang   

  1. VIP Clinic, the Third Affiliated Hospital of Naval Medical University, Shanghai 200438, China
  • Received:2025-06-22 Published:2025-12-10
  • Corresponding author: Shuheng Fang
引用本文:

朱恒美, 董志涛, 房树恒, 贺丹丹, 张晓丽, 周静, 翟健, 耿利, 杨甲梅. 肝癌肝动脉持续灌注化疗患者卧床时限改变的前瞻性研究[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(06): 925-930.

Hengmei Zhu, Zhitao Dong, Shuheng Fang, Dandan He, Xiaoli Zhang, Jing Zhou, Jian Zhai, Li Geng, Jiamei Yang. Prospective study on change of bed rest duration in liver cancer patients undergoing continuous hepatic arterial infusion chemotherapy[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(06): 925-930.

目的

探讨肝癌患者在实施肝动脉灌注化疗(HAIC)期间提前下床活动,对HAIC患者灌注期间安全性与舒适度的影响。

方法

选取2023年12月至2024年3月在海军军医大学第三附属医院行HAIC的102例肝癌患者进行前瞻性研究。其中男92例,女10例;年龄38~66岁,中位年龄55岁。患者均签署知情同意书,符合医学伦理学规定。采用便利抽样法将患者分为对照组与试验组,各51例。对照组按照TACE护理常规,试验组通过检索文献查找最佳循证医学证据,结合我院患者实际情况,予灌注后12 h首次下床。观察比较两组患者不良事件、并发症情况、舒适度、满意度等指标。两组疲劳及舒适度评分比较采用t检验;满意度等比较采用χ2检验。

结果

试验组与对照组不良事件发生率均无统计学意义(P>0.05),疼痛、失眠、腰背痛、尿潴留、便秘并发症分别为2、3、2、1、2例和11、14、21、7、9例,差异有统计学意义(χ2=7.141,8.541,20.265,4.883,4.993;P<0.05)。试验组患者疲劳及舒适度评分分别为(54.6±2.7)、(89.1±0.7)分,对照组相应为(78.1±3.2)、(71.5±1.2)分,差异有统计学意义(t=-9.255,6.176;P<0.05);试验组患者满意度为98%(50/51),明显高于对照组的78%(40/51) (χ2=9.444,P<0.05)。

结论

对肝癌患者行HAIC灌注期间,术后12 h提前下床活动对HAIC灌注期间安全无影响,卧床时限改变可提高患者的舒适度,提高患者满意度。

Objective

To evaluate the effect of early off-bed activity on the safety and level of comfort of patients with liver cancer during hepatic arterial infusion chemotherapy (HAIC).

Methods

In this prospective study, 102 patients with liver cancer who underwent HAIC in the Third Affiliated Hospital of Naval Military Medical University from December 2023 to March 2024 were enrolled. Among them, 92 patients were male and 10 female, aged from 38 to 66 years, with a median age of 55 years. The informed consents of all patients were obtained and the local ethical committee approval was received. All patients were divided into the control (n=51) and study groups (n=51) based on convenient sampling method. Patients in the control group received TACE routine nursing. In the study group, the optimal evidence-based medical evidence was obtained through literature retrieval. Combined with the actual status of patients, they were advised for first off-bed activity at 12 h after HAIC. The incidence of adverse events, complications, level of comfort and degree of satisfaction were observed and compared between two groups. Fatigue and level of comfort scores were compared by t-test. The degree of satisfaction was compared by Chi-square test.

Results

There was no statistically significant difference in the incidence of adverse events between the study groups and the control group. In the study and control groups, 2, 3, 2, 1, 2 and 11, 14, 21, 7 and 9 patients developed pain, insomnia, low back pain, urine retention and constipation, and the differences were statistically significant (χ2=7.141, 8.541, 20.265, 4.883, 4.993; all P<0.05). The scores of fatigue and level of comfort in the study group were 54.6±2.7 and 89.1±0.7, while 78.1±3.2 and 71.5±1.2 in the control group, and the differences were statistically significant (t=-9.255, 6.176; both P<0.05). The degree of satisfaction of patients in the study group was 98%(50/51), significantly higher than 78%(40/51) in the control group (χ2=9.444, P<0.05).

Conclusions

Off-bed activity at 12 h after HAIC exerts no effects on the safety of patients with liver cancer during HAIC. Changing bed rest duration can elevate the level of comfort, and improve the degree of satisfaction of patients.

表1 两组行HAIC肝癌患者一般资料比较
表2 两组HAIC的肝癌患者不良事件和并发症比较(例)
表3 两组行HAIC的肝癌患者疲劳、舒适度及满意度比较
[1]
中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(4): 407-449. DOI: 10.3877/cma.j.issn.2095-3232.2024.04.001.
[2]
肝细胞癌经动脉化疗栓塞治疗围术期护理策略专家共识[J].临床放射学杂志, 2022, 41(2): 212-216. DOI: 10.13437/j.cnki.jcr.2022.02.036.
[3]
姚玲玉, 崔霞, 王晓云. 经股动脉入路介入术后患者制动时间的最佳证据总结[J]. 中国临床护理, 2022, 14(8): 478-483. DOI: 10.3969/j.issn.1674-3768.2022.08.005.
[4]
陈静, 黄雨滟, 陈琪, 等. 加速康复理念下经导管动脉栓塞化疗肝癌患者管理的证据总结[J]. 中国护理管理, 2022, 22(9): 1371-1377. DOI: 10.3969/j.issn.1672-1756.2022.09.020.
[5]
国家肿瘤微创治疗产业技术创新战略联盟护理专业委员会, 中国抗癌协会肿瘤介入学专业委员会. 肝动脉灌注化疗持续动脉给药及管路护理专家共识[J]. 介入放射学杂志, 2023, 32(6): 519-526. DOI: 10.3969/j.issn.1008-794X.2023.06.001.
[6]
中国抗癌协会肝癌专业委员会. 肝动脉灌注化疗治疗肝细胞癌中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(7): 754-759. DOI: 10.3760/cma.j.cn115610-20210618-00288.
[7]
王姿涵. 肝癌介入术后病人护理干预研究进展[J]. 全科护理, 2020, 18(28): 3774-3776. DOI: 10.12104/j.issn.1674-4748.2020.28.009.
[8]
Liu Q, Zhang Y, Zhang J, et al. Efficacy and safety of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk[J]. Front Oncol, 2024, 14: 1374149. DOI: 10.3389/fonc.2024.1374149.
[9]
Lyu N, Wang X, Li JB, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase Ⅲ trial (FOHAIC-1)[J]. J Clin Oncol, 2022, 40(5): 468-480. DOI: 10.1200/JCO.21.01963.
[10]
唐英, 闫雪琴, 张志刚, 等. 肝癌介入术后早期下床活动时间的Meta分析[J]. 中国实用护理杂志, 2017, 33(10): 791-796.
[11]
莫伟, 向华, 阳秀春, 等. 股动脉穿刺介入术后制动时间的循证证据研究[J]. 介入放射学杂志, 2019, 28(1): 85-88. DOI: 10.3969/j.issn.1008-794X.2019.01.018.
[12]
李含英, 尤国美, 潘琴, 等. 经桡动脉置管行持续灌注化疗治疗肝癌的安全性和舒适性研究[J]. 浙江医学, 2020, 42(21): 2366-2367, 2373.
[13]
何宁宁, 周利平, 薛冰, 等. 肝癌术后早期下床活动方案的构建及应用[J]. 护理学杂志, 2020, 35(1): 24-28. DOI: 10.3870/j.issn.1001-4152.2020.01.024.
[14]
中国抗癌协会肿瘤麻醉与镇痛专业委员会. 中国肿瘤患者围术期疼痛管理专家共识(2020版)[J]. 中国肿瘤临床, 2020, 47(14): 703-710. DOI: 10.3870/j.issn.1000-8179.2020.14.584.
[15]
An C, Wei R, Yao W, et al. Association of serum AFP trajectories and hepatocellular carcinoma outcomes after hepatic arterial infusion chemotherapy: a longitudinal, multicenter study[J]. Cancer Med, 2024, 13(11): e7319. DOI: 10.1002/cam4.7319.
[16]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[17]
Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6. DOI: 10.1038/s41572-020-00240-3.
[18]
陈敏山, 胡自力. 肝动脉灌注化疗在肝癌转化治疗中的研究进展[J]. 中华消化外科杂志, 2021, 20(2): 171-177. DOI: 10.3760/cma.j.cn115610-20201230-00813.
[19]
赵晓芸, 孙兴伟, 陈香凤, 等. 肝动脉灌注化疗患者舒适性提升的前瞻性研究[J]. 介入放射学杂志, 2022, 31(5): 499-502. DOI: 10.3969/j.issn.1008-794X.2022.05.016.
[20]
杨俊, 印于, 张申, 等. HAIC序贯TAE治疗不可切除肝细胞癌的安全性和有效性[J]. 介入放射学杂志, 2023, 32(3): 229-232. DOI: 10.3969/j.issn.1008-794X.2023.03.005.
[21]
元云飞. 肝癌转化治疗后外科切除的必要性和手术时机[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12(1): 11-15. DOI: 10.3877/cma.j.issn.2095-3232.2023.01.003.
[22]
王志强, 彭俏菁, 黎源, 等. 经股动脉DSA术后下肢不同制动时间对并发症发生率的影响[J]. 哈尔滨医药, 2021, 41(3): 65-66.
[23]
王洁, 李含英, 吕展杨, 等. 肝动脉灌注化疗的围手术期护理[J]. 介入放射学杂志, 2024, 33(4): 431-437. DOI: 10.3969/j.issn.1008-794X.2024.04.016.
[24]
卢利云. 6例肝动脉灌注化疗治疗晚期原发性肝癌的护理体会[J]. 加速康复外科杂志, 2020, 3(3): 123-126.
[25]
周奔, 吴涯昆. 肝动脉灌注化疗在肝癌转化治疗中的应用进展[J]. 医学理论与实践, 2024, 37(5): 748-750, 744. DOI: 10.19381/j.issn.1001-7585.2024.05.008.
[26]
中国抗癌协会肿瘤介入学专业委员会, 中国抗癌协会肿瘤介入学专业委员会化疗与免疫治疗分委会. 改良式经皮肝动脉化疗药盒植入技术中国专家共识(2022版)[J]. 介入放射学杂志, 2022, 31(7): 633-641. DOI: 10.3969/j.issn.1008-794X.2022.07.001.
[27]
潘国芬, 胡梦瑶, 柏祥云, 等. 肝细胞肝癌经肝动脉灌注化疗栓塞术后快速康复外科理念康复的研究[J]. 中华保健医学杂志, 2022, 24(4): 287-290. DOI: 10.3969/j.issn.1674-3245.2022.04.009.
[28]
赵东旭, 张磊, 姜小庆, 等. HAIC是老技术还是新方法——理性看待肝动脉灌注化疗[J]. 介入放射学杂志, 2022, 31(1): 2-8. DOI: 10.3969/j.issn.1008-794X.2022.01.001.
[29]
徐永康, 付舒敏, 李丹, 等. 肝动脉灌注化疗联合系统治疗在原发性肝癌中的研究进展[J]. 介入放射学杂志, 2023, 32(1): 94-97. DOI: 10.3969/j.issn.1008-794X.2023.01.022.
[30]
中国医师协会介入医师分会临床诊疗指南专委会. 肝细胞癌经动脉化疗栓塞抵抗及后续治疗专家共识[J]. 介入放射学杂志, 2022, 31(11): 1039-1044. DOI: 10.3969/j.issn.1008-794X.2022.11.001.
[1] 梁于勇, 郑丽, 杨俭. PDCD4与原发性肝细胞癌患者肝切除术后疾病进展的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(06): 666-669.
[2] 汤震平, 曾鹏飞, 柏斗胜. 绕肝悬吊前入路与传统入路右半肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(06): 670-673.
[3] 李婷婷, 李宏羽, 吴孟航. 肝动脉灌注化疗在不可切除肝细胞癌中的应用进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(06): 705-708.
[4] 吴哲境, 李敬东. ICG荧光成像引导下腹腔镜肝切除术治疗肝癌的安全性和有效性Meta分析[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(06): 852-859.
[5] 黄少坚, 梁汉标, 李清平, 唐善华, 李青妍, 李芷西, 黄灿, 王小振, 陈灿辉, 王恺, 李川江. 基于影像组学和临床特征构建肝癌新辅助/转化治疗后病理学完全缓解预测模型[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(06): 860-867.
[6] 王利皓, 罗世超, 唐强, 尚栋良, 段少博, 卢冰, 李海, 薛飞. 仑伐替尼和PD-1抑制剂预处理联合TACE序贯治疗CNLC分期Ⅲ期肝癌疗效及安全性[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(06): 868-874.
[7] 李健文, 陈莹, 陈羲, 宗晓丹. 钆塞酸二钠增强MRI在高分化小肝癌和不典型增生结节鉴别诊断中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(06): 875-881.
[8] 余萱, 贺需旗, 郭光辉, 谭雷, 李凯, 曾庆劲. 新型微波消融系统治疗血管旁与非血管旁肝癌的安全性及疗效[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(06): 888-893.
[9] 段兴福, 唐建中, 孙志为, 陈业盛, 高波, 费振浩. 后腹膜入路腹腔镜微波消融术治疗复发性肝癌的临床疗效[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(06): 919-924.
[10] 袁洳靖, 孙居仙, 程树群. 肝癌合并门静脉癌栓放射治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(05): 659-666.
[11] 张燕, 许丁伟, 胡满琴, 黄昊扬, 宋光娜, 黄洁. 术前免疫炎症指标对肝癌肝切除术患者生存预后的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(05): 707-715.
[12] 方兴保, 庞国莲, 李月宏, 蔡艳. 基于多组学分析MCAM在肝癌中表达及其与生存预后和免疫细胞浸润的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(05): 716-724.
[13] 唐善华, 赖展鸿, 刘海晴, 王小振, 王恺, 周杰. 基于XGBoost算法构建肝癌肝切除术后肝衰竭早期识别预测模型[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(05): 725-731.
[14] 赵俊宇, 林航宇, 李会灵, 王显飞, 游川. 肝癌肝切除术后大量腹水预测模型的建立与验证[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(05): 740-747.
[15] 胡铭语, 李敬东, 肖雨竹, 黄杰. 初始不可切除肝癌患者转化治疗序贯手术的临床疗效分析[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(05): 754-760.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?